For servers in cell B to accept the identity assertion, the upstream server in cell a must authenticate itself first.
对于计算单元b中接受标识断言的服务器,计算单元a中的上游服务器必须首先对自身进行身份验证。
A two - (or more) cell strategy provides the capability to divert traffic to an alternate cell (cell b) while maintenance is being applied to a primary cell (cell a).
在您对主要单元(单元a)进行维护时,一个两单元(或者多单元)策略可以使流量转移到一个可替换的单元(单元b)。
If you do not want cell a to trust cell b, use certificate authentication for the server to server authentication step, not basic auth.
如果不希望计算单元a信任计算单元b,则请在服务器身份验证步骤中为服务器使用证书身份验证,而不是采用基本身份验证。
Similarly, if any problems are discovered after cell a is activated after the changes are applied, it can simply be shut down and all traffic will flow to cell b.
类似地,如果在对单元a应用更改并激活后出现问题,只需要关闭单元a,所有流量将会流入单元b。
In this case, you create a color instance and use it to set a particular pixel within the display window (see Listing 2 and Figure 3, cell b).
在本例中,我们创建了一个颜色实例并用它来设置显示窗口内的某个像素点(参见清单2和图3中的cell b)。
Background: MZL are uncommon B-cell lymphomas.
背景:边缘区淋巴瘤是比较少见的B细胞淋巴瘤。
B-cell lymphoma was the predominant type, seen in 42 of 45 cases (93.3%).
其中B细胞性淋巴瘤是最常见的病理类型,占93.3%(42/45)。
Conclusion Most cases were B-cell type lymphoma with low-grade malignancy.
结论11例胃malt淋巴瘤中大多数示低度恶性B细胞性淋巴瘤。
The biological immune system employs B-Cell and T-Cell in detecting antigen.
在机体免疫系统中,B淋巴细胞和T淋巴细胞协同起来识别抗原。
It is always the non-Hodgkin type, and the vast majority are B-cell lymphomas.
几乎全部都是非霍奇金淋巴瘤,而且绝大部分为B细胞淋巴瘤。
Results All the 11cases were B-cell type lymphoma, and male patients were more common.
结果11例胃MALT淋巴瘤全部示B细胞性淋巴瘤,且男性多于女性。
Selection and identification of B-cell epitopes are important for tumor vaccine designing.
因此,筛选并鉴定肿瘤B细胞表位对肿瘤疫苗设计具有重要意义。
The B-cell receptor also represents an important target for patients with B-cell malignancies.
对于B细胞淋巴瘤患者,B细胞受体也代表着一个很重要的药物标靶。
Background: MZL are uncommon B-cell lymphomas. The outcomes and prognostic factors of MZL remain poorly defined.
背景:边缘区淋巴瘤是比较少见的B细胞淋巴瘤。边缘区淋巴瘤的转归和预后因子尚不明确。
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules.
本申请总体来说提供了用CD37 -特异性结合分子在个体中减少B -细胞的方法。
CD200 staining by flow cytometry can be useful in the differential diagnosis of B-cell neoplasms and in their detection in the BM.
通过流式细胞仪检测,CD 200染色可用于B细胞肿瘤的鉴别诊断和BM检查。
Multiple novel targeted agents are emerging for B-cell malignancies, but few studies have successfully and safely combined these agents.
现在出现了多种治疗B细胞恶性肿瘤的新型靶向药物,但是很少有研究成功并安全地联合这些药物。
Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging.
通过流式细胞仪检测CD 200在B细胞肿瘤中的差异性表达可以协助诊断、分类与骨髓分期。
Objective To discuss further scientific, brief and applied Math Judgment Method about the Function of Pancreas B-cell and Insulin Resistance.
目的进一步探讨胰岛B细胞功能及胰岛素抵抗科学、简便、实用的数学判定法。
Insulin resistance and B-cell dysfunction are the two main components in the pathogenesis of type 2 diabetes, and insulin resistance is initial factor.
胰岛素抵抗和B细胞功能障碍是2型糖尿病发病机制的两个主要环节,而胰岛素抵抗是2型糖尿病发生的始动因素。
Moreover, 61 (90%) of 68 of NK cell neoplasms demonstrated CD335 expression, whereas B-cell, myelomonocytic, and plasma cell neoplasms lacked expression.
此外,在68例nk细胞肿瘤中有61例(90%)表达CD335,而B细胞肿瘤、骨髓单核细胞肿瘤、浆细胞瘤则缺乏表达。
Objective to observe the effect and toxicity of rituximab and CHOP regimen (R-CHOP) in the treatment of initially diagnosed diffuse large B-cell lymphoma.
目的观察利妥昔单抗联合CHOP方案(R - CHOP)治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
To analyze CD200 expression by flow cytometry in a large series of B-cell neoplasms in a variety of tissue types in comparison with benign B-lineage cells.
通过流式细胞仪检测,分析在一系列各种组织类型的B细胞肿瘤中CD200表达情况,并与良性B系细胞进行比较。
Objective: To investigate the BCL-6 gene alterations in B-cell Non-Hodgkin's lymphomas (B-NHL) in Chinese populations and its clinic-pathological significance.
目的:系统性地研究中国人B - NHL常见类型中bcl - 6基因的异常,并探讨其临床病理意义。
While, monoclonal antibody against CD20 antigen on the membrane of B-cell NHLs and normal B-lymphocyte showed satisfactory curative effect in clinical treatment of NHL.
针对B淋巴瘤细胞和B淋巴细胞表面CD 20抗原的单克隆抗体治疗NHL取得了较好的效果。
Objectives To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas(B-NHL).
目的评价德国NHL-BFM-90方案治疗中国儿童青少年B细胞非霍奇金淋巴瘤(B-NHL)的疗效和毒性。
Conclusions Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
结论弥漫性大B细胞性淋巴瘤治疗后生存期可通过肿瘤微环境中的免疫细胞、纤维化、血管形成的差异而影响。
BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated.
在109例可评价的病例中,有108例(99%)BRISH检测轻链限制性(LCR)的结果与流式细胞仪一致,并成功评估了另外的小B细胞淋巴瘤病例组。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景:目前,弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景:目前,弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
应用推荐